UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 335

Sortiert nach

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

The Lancet (British edition), 2022-01, Vol.399 (10320), p.161-171

2022

Volltextzugriff (PDF)

Mechanically Adaptive Polymers Constructed from Dynamic Coordination Equilibria

Angewandte Chemie International Edition, 2024-04, Vol.63 (17), p.e202400758-n/a

International ed. in English, 2024

Volltextzugriff (PDF)

Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? – Authors' reply

The Lancet (British edition), 2022-09, Vol.400 (10355), p.808-809

2022

Volltextzugriff (PDF)

A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal Trials

Clinical pharmacology and therapeutics, 2022-05, Vol.111 (5), p.1050-1060

2022

Volltextzugriff (PDF)

Validation of 4β‐hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

British journal of clinical pharmacology, 2014-11, Vol.78 (5), p.1122-1134

2014

Volltextzugriff (PDF)

Improving the assessment of the probability of success in late stage drug development

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2022-03, Vol.21 (2), p.439-459

2022

Volltextzugriff (PDF)

Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case study

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2022-09, Vol.21 (5), p.1005-1021

2022

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.3101-3106

2012

Volltextzugriff (PDF)

A randomized clinical trial to evaluate the single‐dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes

Pediatric diabetes, 2019-02, Vol.20 (1), p.48-56

2019

Volltextzugriff (PDF)

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

Journal of the American Society of Nephrology, 2018-07, Vol.29 (7), p.1979-1991

2018

Volltextzugriff (PDF)

Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19628-n/a

2014

Volltextzugriff (PDF)

Non-white noise in fMRI: Does modelling have an impact?

NeuroImage (Orlando, Fla.), 2006, Vol.29 (1), p.54-66

2006

Volltextzugriff (PDF)

On the Use of Group Sequential Study Designs for the Test of Bioequivalence for Complicated Products

Journal of pharmaceutical sciences, 2017-10, Vol.106 (10), p.3167-3170

2017

Volltextzugriff (PDF)

Laropiprant in Combination With Extended-Release Niacin Does Not Alter Urine 11-Dehydrothromboxane B2, a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

Journal of clinical pharmacology, 2009-12, Vol.49 (12), p.1426-1435

2009

Volltextzugriff (PDF)

Multiple-Dose Administration of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Alter the Single-Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects

Journal of clinical pharmacology, 2007-02, Vol.47 (2), p.159-164

2007

Volltextzugriff (PDF)

Diagnosis of single-subject and group fMRI data with SPMd

Human brain mapping, 2006-05, Vol.27 (5), p.442-451

2006

Volltextzugriff (PDF)

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D 2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

Journal of clinical pharmacology, 2010-11, Vol.50 (11), p.1273-1279

2010

Volltextzugriff (PDF)

Mechanically Adaptive Polymers Constructed from Dynamic Coordination Equilibria

Angewandte Chemie, 2024-04, Vol.136 (17), p.n/a

2024

Volltextzugriff (PDF)

Biochemical and microbial properties of rhizospheres under maize/ peanut intercropping

Journal of Integrative Agriculture, 2016-01, Vol.15 (1), p.101-110

2016

Volltextzugriff (PDF)

(1a R ,5a R )1a,3,5,5a-Tetrahydro-1 H -2,3-diaza-cyclopropa[ a ]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans

Journal of medicinal chemistry, 2012-04, Vol.55 (8), p.3644-3666

2012

Volltextzugriff (PDF)

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

Biopharmaceutics & drug disposition, 2007-09, Vol.28 (6), p.307-313

2007

Volltextzugriff (PDF)

Effects of Multiple Doses of Clarithromycin on the Pharmacokinetics of Laropiprant in Healthy Subjects

Cardiovascular therapeutics, 2011-04, Vol.29 (2), p.140-145

2011

Volltextzugriff (PDF)

The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin

Platelets (Edinburgh), 2014-11, Vol.25 (7), p.480-487

2014

Volltextzugriff (PDF)

Laropiprant in Combination With Extended‐Release Niacin Does Not Alter Urine 11‐Dehydrothromboxane B 2 , a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

Journal of clinical pharmacology, 2009-12, Vol.49 (12), p.1426-1435

2009

Volltextzugriff (PDF)

Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome

Annals of the rheumatic diseases, 2022-07, Vol.81 (7), p.979

2022

Volltextzugriff (PDF)

1 – 25 von 335

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(272)
Mit Volltextzugriff
(292)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(196)
Life Sciences & Biomedicine
(110)
Humans
(74)
Technology
(55)
Male
(48)
Physical Sciences
(48)
Female
(46)
Adult
(35)
Middle Aged
(35)
Animals
(31)
Physics
(26)
Materials Science
(25)
Engineering
(24)
Chemistry
(23)
Materials Science, Multidisciplinary
(21)
Pharmacology & Pharmacy
(21)
Aged
(19)
Young Adult
(17)
Adolescent
(16)
Engineering, Electrical & Electronic
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Mechanically Adaptive Polymers Constructed from Dynamic Coordination Equilibria

Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? – Authors' reply

A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal Trials

Validation of 4β‐hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

Improving the assessment of the probability of success in late stage drug development

Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case study

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

A randomized clinical trial to evaluate the single‐dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone

Non-white noise in fMRI: Does modelling have an impact?

On the Use of Group Sequential Study Designs for the Test of Bioequivalence for Complicated Products

Laropiprant in Combination With Extended-Release Niacin Does Not Alter Urine 11-Dehydrothromboxane B2, a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

Multiple-Dose Administration of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Alter the Single-Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects

Diagnosis of single-subject and group fMRI data with SPMd

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D 2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

Mechanically Adaptive Polymers Constructed from Dynamic Coordination Equilibria

Biochemical and microbial properties of rhizospheres under maize/ peanut intercropping

(1a R ,5a R )1a,3,5,5a-Tetrahydro-1 H -2,3-diaza-cyclopropa[ a ]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

Effects of Multiple Doses of Clarithromycin on the Pharmacokinetics of Laropiprant in Healthy Subjects

The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin

Laropiprant in Combination With Extended‐Release Niacin Does Not Alter Urine 11‐Dehydrothromboxane B 2 , a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome

Suchergebnisse filtern